Curated CRC research — accessible, accurate, actionable

The CRC Digest

Tuesday, September 01, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ◆ TRIAL DATA

  Phase 3 ANCHOR trial compares anlotinib to bevacizumab plus chemotherapy in RAS/BRAF wild-type metastatic CRC

  This multicenter, randomized phase 3 trial evaluated first-line anlotinib versus bevacizumab plus CapeOX in patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer. (Nature via Google News)

• ◇ RESEARCH

  Mutant allele frequency in ctDNA may guide EGFR rechallenge decisions in metastatic CRC

  Research published in JCO Precision Oncology explores how relative mutant allele frequency in circulating tumor DNA (ctDNA) could help determine when to rechallenge patients with anti-EGFR therapy after resistance develops. (JCO Precision Oncology)

• ◇ RESEARCH

  Bispecific antibody co-targeting EGFR and CDH17 reduces skin toxicity in preclinical CRC models

  A bispecific antibody co-targeting EGFR and cadherin-17 (CDH17) achieved superior tumor growth inhibition compared to EGFR- or c-MET/EGFR-targeting antibodies while reducing skin-related toxicities in preclinical colorectal cancer studies. The high-affinity CDH17-binding arm anchored the antibody to tumor cell surfaces, facilitating rapid engagement of EGFR through an "anchor and capture" mechanism. (Cancer Research)

Today's research highlights advances in precision medicine—from liquid biopsy to guide treatment decisions to novel therapies designed to reduce side effects—and continued progress in screening access for younger adults.